Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature-Reference-Cited by-同舟云学术

Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature

Published:2011-10-28 Issue:3 Volume:14 Page:259-267
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Chawla J.S.¹,Ghobadi A.¹,Mosley J.¹,Verkruyse L.¹,Trinkaus K.²,Abboud C.N.¹,Cashen A.F.¹,Stockerl-Goldstein K.E.¹,Uy G.L.¹,Westervelt P.¹,DiPersio J.F.¹,Vij R.¹

Affiliation:

1. Division of Oncology; Washington University School of Medicine; Saint Louis; Missouri; USA

2. Biostatistics; Washington University School of Medicine; Saint Louis; Missouri; USA

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1399-3062.2011.00689.x/fullpdf

Reference35 articles.

1. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan;Kanda;Bone Marrow Transplant,2001

2. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection;Qamruddin;Bone Marrow Transplant,2001